Kalaris Therapeutics, Inc.
KLRS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001754068
No open-market purchases or sales by Kalaris Therapeutics, Inc. insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $73.4M in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in Kalaris Therapeutics, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 51
- +19 vs. Q3 2025
- Shares held
- 18.0M
- +4.77M (+36.1%) vs. Q3 2025
- Total value
- $151.9M
- +$75.5M (+98.7%) vs. Q3 2025
- New holders
- 24
- 10 more added
- Sold out
- 5
- 7 more reduced
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KLRS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 56 | $73.4M |
| Q1 2026 | 58 | $107.2M |
| Q4 2025 | 51 | $151.9M |
| Q3 2025 | 32 | $76.4M |
| Q2 2025 | 30 | $35.7M |
| Q1 2025 | 32 | $111.4M |
| Q4 2024 | 53 | $20.7M |
| Q3 2024 | 60 | $36.3M |
| Q2 2024 | 72 | $33.9M |
| Q1 2024 | 77 | $36.4M |
| Q4 2023 | 82 | $28.5M |
| Q3 2023 | 90 | $115.5M |
| Q2 2023 | 94 | $183.6M |
| Q1 2023 | 89 | $156.0M |
| Q4 2022 | 86 | $193.1M |
| Q3 2022 | 87 | $293.7M |
| Q2 2022 | 84 | $109.6M |
| Q1 2022 | 84 | $184.1M |
| Q4 2021 | 84 | $329.4M |
| Q3 2021 | 80 | $640.3M |
| Q2 2021 | 84 | $521.8M |
| Q1 2021 | 75 | $624.4M |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Kalaris Therapeutics, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Samsara BioCapital, LLC | 12,948,081 | $109.3M | 11.27% | +1,500,000+13.1% | Added |
| RTW Investments, LP | 1,300,000 | $11.0M | 0.11% | +1,300,000 | New |
| Paradigm Biocapital Advisors LP | 700,000 | $5.91M | 0.16% | +700,000 | New |
| Siren, L.L.C. | 435,798 | $3.68M | 0.11% | +117,534+36.9% | Added |
| Alyeska Investment Group, L.P. | 403,551 | $3.40M | 0.01% | +403,551 | New |
| Ikarian Capital, LLC | 360,000 | $3.04M | 0.39% | +360,000 | New |
| Vanguard Group Inc | 292,790 | $2.47M | 0.00% | +89,739+44.2% | Added |
| Kalehua Capital Management LLC | 139,901 | $1.18M | 1.17% | +139,901 | New |
| Woodline Partners LP | 100,000 | $844.0K | 0.00% | −141,102−58.5% | Reduced |
| ADAR1 Capital Management, LLC | 100,000 | $844.0K | 0.06% | +100,000 | New |
| Whi Trust Co LLC | 97,493 | $822.8K | 0.63% | +97,493 | New |
| Boothbay Fund Management, LLC | 92,261 | $778.7K | 0.02% | +92,261 | New |
| Raymond James Financial Inc | 88,436 | $746.4K | 0.00% | +88,436 | New |
| Renaissance Technologies LLC | 87,751 | $740.6K | 0.00% | −25,000−22.2% | Reduced |
| Redmile Group, LLC | 82,955 | $700.1K | 0.05% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 82,647 | $697.6K | 0.00% | +18,096+28.0% | Added |
| 683 Capital Management, LLC | 80,590 | $680.2K | 0.06% | +80,590 | New |
| Marshall Wace, LLP | 72,876 | $615.1K | 0.00% | +58,761+416.3% | Added |
| Propel Bio Management, LLC | 42,053 | $354.9K | 0.30% | +42,053 | New |
| Belpointe Asset Management LLC | 40,000 | $337.6K | 0.01% | 00.0% | Unchanged |
| Fortis Capital Advisors, LLC | 40,000 | $337.6K | 0.05% | 00.0% | Unchanged |
| BlackRock, Inc. | 38,454 | $324.6K | 0.00% | −1,925−4.8% | Reduced |
| Goldman Sachs Group Inc | 34,303 | $289.5K | 0.00% | +11,838+52.7% | Added |
| Jane Street Group, LLC | 33,114 | $279.5K | 0.00% | +33,114 | New |
| Omers Administration Corp | 30,000 | $253.2K | 0.00% | +30,000 | New |
| Morgan Stanley | 27,948 | $235.9K | 0.00% | +3,030+12.2% | Added |
| Two Sigma Investments, LP | 27,759 | $234.3K | 0.00% | +27,759 | New |
| State Street Corp | 25,410 | $214.5K | 0.00% | +2,800+12.4% | Added |
| Squarepoint Ops LLC | 25,367 | $214.1K | 0.00% | −14,806−36.9% | Reduced |
| Bridgeway Capital Management, LLC | 22,500 | $189.9K | 0.00% | 00.0% | Unchanged |
| Simplify Asset Management Inc. | 20,074 | $169.4K | 0.00% | +20,074 | New |
| RBF Capital, LLC | 17,391 | $146.8K | 0.01% | 00.0% | Unchanged |
| Northern Trust Corp | 13,654 | $115.2K | 0.00% | +13,654 | New |
| Susquehanna International Group, LLP | 12,856 | $108.5K | 0.00% | +12,856 | New |
| Walleye Capital LLC | 11,225 | $94.7K | 0.00% | +11,225 | New |
| XTX Topco Ltd | 10,897 | $92.0K | 0.00% | +10,897 | New |
| Keel Point, LLC | 10,225 | $86.3K | 0.01% | +10,225 | New |
| Connor, Clark & Lunn Investment Management Ltd. | 10,159 | $85.7K | 0.00% | +10,159 | New |
| Johnson Financial Group, Inc. | 10,000 | $84.4K | 0.00% | 00.0% | Unchanged |
| FMR LLC | 7,806 | $65.9K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 6,704 | $56.6K | 0.00% | +6,487+2,989.4% | Added |
| Barclays PLC | 6,065 | $51.2K | 0.00% | +6,065 | New |
| Nano Cap New Millennium Growth Fund L P | 4,000 | $33.8K | 0.03% | +4,000 | New |
| UBS Group AG | 2,691 | $22.7K | 0.00% | −2,561−48.8% | Reduced |
| Royal Bank of Canada | 113 | $1.00K | 0.00% | +28+32.9% | Added |
| Fortitude Family Office, LLC | 114 | $962 | 0.00% | +114 | New |
| BNP Paribas Arbitrage, SA | 52 | $439 | 0.00% | −89−63.1% | Reduced |
| JPMorgan Chase & Co | 50 | $422 | 0.00% | 00.0% | Unchanged |
| Parallel Advisors, LLC | 49 | $414 | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 5 | $42 | 0.00% | −3−37.5% | Reduced |
| Citigroup Inc | 1 | $8 | 0.00% | 00.0% | Unchanged |
| Tang Capital Management LLC | 0 | $0 | 0.00% | −418,241−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −24,923−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −578−100.0% | Sold out |
| Strengthening Families & Communities, LLC | 0 | $0 | 0.00% | −268−100.0% | Sold out |
| Farther Finance Advisors, LLC | 0 | $0 | 0.00% | −33−100.0% | Sold out |